BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 6977241)

  • 1. [Immunological data in the clinical evaluation of Hodgkin's diseases].
    Burchardt K
    Z Gesamte Inn Med; 1981 Nov; 36(21):840. PubMed ID: 6977241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persisting lymphocyte deficiences during remission in Hodgkin's disease.
    Björkholm M; Holm G; Mellstedt H
    Clin Exp Immunol; 1977 Jun; 28(3):389-93. PubMed ID: 302164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Proportions and absolute count of T- and B-lymphocytes in peripheral blood and their blastic transformation induced by mitogens in splenectomized and non-splenectomized patients with Hodgkin's disease].
    Pluzańska A
    Acta Haematol Pol; 1978; 9(1):37-44. PubMed ID: 307325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hodgkin's disease. T lymphocyte defect in patients in complete remission (author's transl)].
    Lang JM; Bigel P; Oberling F; Mayer S
    Pathol Biol (Paris); 1978; 26(3-4):159-62. PubMed ID: 355984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hodgkin's disease. T lymphocyte defect in patients in complete remission (author's transl)].
    Lang JM; Bigel P; Oberling F; Mayer S
    Sem Hop; 1978 Nov 8-15; 54(37-40):1155-8. PubMed ID: 217096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinguishing features of the immunology of Hodgkin's disease in children.
    Tan CT; De Sousa M; Good RA
    Cancer Treat Rep; 1982 Apr; 66(4):969-75. PubMed ID: 7074657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immune profile in patients with Hodgkin's disease in long-term remission after cytostatic chemotherapy].
    Nagel GA; Pietra CD; Hartmann D; Rosenthal M; Albrecht R; Obrist R; Obrecht P
    Schweiz Med Wochenschr; 1979 Jan; 109(2):45-51. PubMed ID: 311514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune condition in patients with Hodgkin's disease.
    Zywicka-Lopaciuk H; Konopka L; Traczyk Z; Pawelski S; Sylwestrowicz T; Maślanka K; Arczyńska-Brojer E; Cieśluk S; Karpowicz M; Małkowska-Zwierz W
    Arch Immunol Ther Exp (Warsz); 1980; 28(1):153-60. PubMed ID: 6968189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired lymphocyte transformation in Hodgkin's disease. Evidence for depletion of circulating t-lymphocytes.
    Matchett KM; Huang AT; Kremer WB
    J Clin Invest; 1973 Aug; 52(8):1908-17. PubMed ID: 4541673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restoration of cellular immune response by levamisole in patients with Hodgkin's disease.
    Levo Y; Rotter V; Ramot B
    Biomedicine; 1975 Jun; 23(6):198-200. PubMed ID: 1082352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed cutaneous hypersensitivity and blood lymphocyte count in advanced Hodgkin's and non-Hodgkin's lymphomas.
    Gupta S; Seth SK; Udupa KN; Sen PC; Rastogi BL
    Ann Chir Gynaecol; 1980; 69(2):79-83. PubMed ID: 7377739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphocyte populations of non-scleronodular Hodgkin's disease subtypes in different stages of lymphocyte depletion. An immunophenotypic and quantitative study.
    Valente G; Ferrara P; Stramignoni A
    Virchows Arch B Cell Pathol Incl Mol Pathol; 1990; 58(4):289-94. PubMed ID: 1970692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levamisole in the treatment of Hodgkin's disease.
    Berényi E; Kávai M; Szabolcsi M; Szegedi G
    Acta Med Acad Sci Hung; 1979; 36(2):177-85. PubMed ID: 317549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphocyte function in Hodgkin's Disease.
    Benninghoff DL; Girardet R
    Lymphology; 1976 Mar; 9(1):39-42. PubMed ID: 1263573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative study of T and B lymphocytes in Hodgkin's disease.
    Bensa JC; Micouin C; Schaerer R; Sotto JJ; Hollard D
    Biomedicine; 1977 Apr; 26(2):137-44. PubMed ID: 326312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoplastic cells obtained from Hodgkin's disease function as accessory cells for mitogen-induced human T cell proliferative responses.
    Fisher RI; Bates SE; Bostick-Bruton F; Tuteja N; Diehl V
    J Immunol; 1984 May; 132(5):2672-7. PubMed ID: 6609204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SPLEEN/PATHOL.
    Bukowski RM; Noguchi S; Hewlett JS; Deodhar S
    Am J Clin Pathol; 1976 Jan; 65(1):30-9. PubMed ID: 1082240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hodgkin's disease--immunological aspects].
    Plat M; Frank KH; Fleischer J; Plat U; Koslowski R
    Allerg Immunol (Leipz); 1988; 34(3):139-58. PubMed ID: 3057835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune status of untreated patients with Hodgkin's disease and prognosis.
    Björkholm M; Wedelin C; Holm G; Ogenstad S; Johansson B; Mellstedt H
    Cancer Treat Rep; 1982 Apr; 66(4):701-9. PubMed ID: 7074640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subpopulations of human T lymphocytes in patients with Hodgkin's disease before and after treatment.
    Karande AA; Gulwani B; Advani SH; Gangal SG
    Neoplasma; 1982; 29(2):149-59. PubMed ID: 6981068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.